BioSpace News Archive

Kirsten Axelsen is a biopharmaceutical consultant as well as a visiting scholar with the American Enterprise Institute and policy advisor to DLA Piper and Charles River Associates.

Dollars as a global currency, loan, credit, and payment concept. A hand offering 100 US dollars. Minimalist art collage

ADCs

Don’t Call It a Crossover, but Alentis Raises $181M Series D for ADC Work

CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But Alentis is targeting an IPO as early as 2025.

November 12, 2024

·

2 min read

·

Annalee Armstrong

Illustration of hand holding trophy with people coming out of trophy and celebrating

Job Trends

BioSpace Announces 2025 Best Places to Work in Biopharma

BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.

November 12, 2024

·

6 min read

·

Angela Gabriel

June 10, 2020 Sunnyvale / CA / USA - The new 23andme headquarters in Silicon Valley; Based on a saliva sample, 23andMe provides reports about the customer's health, traits and ancestry

Layoffs

23andMe Cuts Headcount by 40%, Drops Drug Discovery Work

In line with the restructuring initiative, 23andMe is looking for strategic opportunities for its pipeline assets, including licensing deals or outright sales.

November 12, 2024

·

2 min read

·

Tristan Manalac

Facade of AstraZeneca's office in Shanghai, China

Earnings

AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the “important” U.S. market.

November 12, 2024

·

3 min read

·

Kate Goodwin

Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.

Gene therapy

Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy

Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated at a lower dose and showed promising efficacy outcomes.

November 12, 2024

·

3 min read

·

Tristan Manalac

Deals

Roche Inks Potential $1.8B Deal With Flare to Target Transcription Factors in Cancer

With $70 million upfront and more than $1.8 billion on the line, Roche will gain access to Flare’s drug discovery engine to bolster its oncology pipeline.

November 12, 2024

·

2 min read

·

Tristan Manalac

Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.

Earnings

Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

November 12, 2024

·

9 min read

·

Annalee Armstrong

Pictured: Bayer's office in Berlin, Germany/iStock

Earnings

Bayer Earnings ‘Not Pretty,’ CEO Bill Anderson Admits As He Urges Calm

Bayer reported a decline of 37% in earnings per share on Tuesday, which sent its stock down 12%. CEO Bill Anderson urged investors to be patient as the company executes on a performance-boosting strategy outlined in March.

November 12, 2024

·

2 min read

·

Annalee Armstrong

vector 3d lungs made of triangular polygons on a blue background

Clinical research

Insilico Aces Second Mid-Stage IPF Trial in a Row

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and was well-tolerated across all dosing groups.

November 12, 2024

·

2 min read

·

Heather McKenzie